Standpoint Research downgrades Pharmaceutical Product Development Inc. (Nasdaq: PPDI) from Buy to Hold.

The firm said, "During the last month PPDI ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE